KOPRAN FORMS NEW COs FOR SSP, R&D
Article Abstract:
Kopran Ltd is spinning off its semi-synthetic penicillin into Kopran Drugs, a new company. It is also hiving off its research and development facilities into Kopran Research Laboratories Ltd (KRLL), a 100 percent subsidiary. KRLL will undertake collaborative research, contract research and transfer of technology. Kopran has hired a global agency for conducting business valuation. It proposes to concentrate on sterile cephalosporins, cardiovasculars and other high value bulks. Kopran aims to post a sales of Rs450 crore by 2001 AD, with exports accounting for Rs250 crore. (ag)
Comment:
Is spinning off semi-synthetic penicillin into Kopran Drugs, new co
Publication Name: Economic Times
Subject: Business, international
ISSN: 0013-0389
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
MAX-GB TO SET UP Rs30 CRORE AMOXYCILLIN UNIT
Article Abstract:
Max-GB Ltd (MGB), a pharmaceutical company, will set up a 1,000 tonnes per annum (tpa) semi synthetic penicillin unit in India. The cost of the project will be Rs30 crore. It plans to float a Rs80 crore convertible debenture issue that has been subscribed by Gist Brocades (GB) of Netherlands. MGB, which is a joint venture between Max India and GB will emerge as one of the largest amoxycillin producers in India after the setting up of the unit at Tonsa in Punjab. (gs)
Comment:
Indian pharmaceutical company will set up a 1,000-tonnes/annum semi-synthetic penicillin unit in India
Publication Name: Economic Times
Subject: Business, international
ISSN: 0013-0389
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
KOPRAN LTD NETS Rs4 CR, SALES AT Rs52 CR
Article Abstract:
Kopran Ltd has declared a net profit of Rs4.05 crore on sales of Rs51.8 crore in the quarter ended September 30, 1998. The company has hived of its semi-synthetic penicillin business into a separate company called Kopran Drugs Ltd. The combined turnover of the two companies is Rs106 crore in the quarter ended September 30, 1998. Kopran Ltd will now concentrate on formulations, speciality bulks and medical electronics. (khr)
Publication Name: Economic Times
Subject: Business, international
ISSN: 0013-0389
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: MJ PHARMA RECORDS NET LOSS OF Rs5.46 CR SUVEN PHARMA INCOME UP AT Rs8.02 CRORE. AUROBINDO PHARMA Q3 TURNOVER UP 60%
- Abstracts: HINDUSTAN MOTORS LIMITED M&M NET SKIDS 26% TO Rs82.8 Cr. HIND MOTORS' RESULTS STAY FLAT
- Abstracts: ITC BHADRA POSTS Rs48-CR LOSS ITC BHADRA TO OFFER SHARES TO PARENT CENTURY TEXTILES IN THE RED WITH Rs85 CRORE LOSS